AGIOS PHARMACEUTICALS, INC. Operating Leases, Rent Expense
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Operating Leases, Rent Expense of $11.40 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2021-02-25
- AGIOS PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2014-12-31 was $1.90M, a 216.67% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2014-09-30 was $700.00K, a 40.00% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2013-12-31 was $600.00K.
- AGIOS PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2013-09-30 was $500.00K.
- AGIOS PHARMACEUTICALS, INC. operating leases, rent expense for fiscal 2018 was $11.40M, a 90.00% increase from fiscal 2017.
- AGIOS PHARMACEUTICALS, INC. operating leases, rent expense for fiscal 2017 was $6.00M, a 0.00% change from fiscal 2016.
- AGIOS PHARMACEUTICALS, INC. operating leases, rent expense for fiscal 2016 was $6.00M, a 15.49% decline from fiscal 2015.
- AGIOS PHARMACEUTICALS, INC. operating leases, rent expense for fiscal 2015 was $7.10M, a 91.89% increase from fiscal 2014.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month | Operating Leases, Rent Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $11.40M 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $6.00M 10-K · filed 2020-02-19 | ||||
| 2016-12-31 | $6.00M 10-K · filed 2019-02-14 | ||||
| 2015-12-31 | $7.10M 10-K · filed 2018-02-14 | $8.60M 10-K · filed 2016-02-26 | |||
| 2014-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $2.60M derived: sum of 2 quarters · filed 2017-02-16 | $3.70M 10-K · filed 2017-02-16 | ||
| 2014-09-30 | $700.00K 10-Q · filed 2014-11-07 | $1.80M 10-Q · filed 2014-11-07 | |||
| 2013-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $1.10M derived: sum of 2 quarters · filed 2016-02-26 | $2.20M 10-K · filed 2016-02-26 | ||
| 2013-09-30 | $500.00K 10-Q · filed 2014-11-07 | $1.60M 10-Q · filed 2014-11-07 | |||
| 2012-12-31 | $2.20M 10-K · filed 2015-02-24 | ||||
| 2011-12-31 | $2.20M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |